nodes	percent_of_prediction	percent_of_DWPC	metapath
Topiramate—CA5B—cervicothoracic ganglion—systemic scleroderma	0.0822	0.568	CbGeAlD
Topiramate—GRIK3—tendon—systemic scleroderma	0.00811	0.056	CbGeAlD
Topiramate—CA7—digestive system—systemic scleroderma	0.00415	0.0287	CbGeAlD
Topiramate—CA12—connective tissue—systemic scleroderma	0.00373	0.0258	CbGeAlD
Topiramate—CA9—digestive system—systemic scleroderma	0.00364	0.0252	CbGeAlD
Topiramate—CA9—tendon—systemic scleroderma	0.00347	0.0239	CbGeAlD
Topiramate—GRIA1—lung—systemic scleroderma	0.00336	0.0232	CbGeAlD
Topiramate—CA12—digestive system—systemic scleroderma	0.0027	0.0186	CbGeAlD
Topiramate—SCN1A—lung—systemic scleroderma	0.00243	0.0168	CbGeAlD
Topiramate—SCN5A—digestive system—systemic scleroderma	0.00234	0.0162	CbGeAlD
Topiramate—CA5B—tendon—systemic scleroderma	0.0023	0.0159	CbGeAlD
Topiramate—CA12—lung—systemic scleroderma	0.00225	0.0155	CbGeAlD
Topiramate—CA1—digestive system—systemic scleroderma	0.00214	0.0147	CbGeAlD
Topiramate—CA5B—lung—systemic scleroderma	0.00202	0.0139	CbGeAlD
Topiramate—CA2—connective tissue—systemic scleroderma	0.00192	0.0132	CbGeAlD
Topiramate—GABRB2—lung—systemic scleroderma	0.0019	0.0131	CbGeAlD
Topiramate—CA1—lung—systemic scleroderma	0.00178	0.0123	CbGeAlD
Topiramate—CA2—smooth muscle tissue—systemic scleroderma	0.00175	0.0121	CbGeAlD
Topiramate—CA2—skin of body—systemic scleroderma	0.00173	0.0119	CbGeAlD
Topiramate—CA4—digestive system—systemic scleroderma	0.00167	0.0115	CbGeAlD
Topiramate—CA4—tendon—systemic scleroderma	0.00159	0.011	CbGeAlD
Topiramate—CYP2C19—digestive system—systemic scleroderma	0.00151	0.0104	CbGeAlD
Topiramate—CA4—lung—systemic scleroderma	0.00139	0.00963	CbGeAlD
Topiramate—CA2—digestive system—systemic scleroderma	0.00138	0.00956	CbGeAlD
Topiramate—CA2—tendon—systemic scleroderma	0.00132	0.0091	CbGeAlD
Topiramate—CA2—lung—systemic scleroderma	0.00116	0.00798	CbGeAlD
Topiramate—CYP3A4—digestive system—systemic scleroderma	0.000893	0.00617	CbGeAlD
Topiramate—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000292	0.000342	CcSEcCtD
Topiramate—Breast disorder—Methotrexate—systemic scleroderma	0.000292	0.000342	CcSEcCtD
Topiramate—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000292	0.000341	CcSEcCtD
Topiramate—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000292	0.000341	CcSEcCtD
Topiramate—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.000291	0.000341	CcSEcCtD
Topiramate—Hypersensitivity—Azathioprine—systemic scleroderma	0.000291	0.00034	CcSEcCtD
Topiramate—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000291	0.00034	CcSEcCtD
Topiramate—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000291	0.00034	CcSEcCtD
Topiramate—Insomnia—Lisinopril—systemic scleroderma	0.00029	0.000339	CcSEcCtD
Topiramate—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000289	0.000338	CcSEcCtD
Topiramate—Paraesthesia—Lisinopril—systemic scleroderma	0.000288	0.000336	CcSEcCtD
Topiramate—Vomiting—Captopril—systemic scleroderma	0.000288	0.000336	CcSEcCtD
Topiramate—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000286	0.000335	CcSEcCtD
Topiramate—Dyspnoea—Lisinopril—systemic scleroderma	0.000286	0.000334	CcSEcCtD
Topiramate—Rash—Captopril—systemic scleroderma	0.000285	0.000333	CcSEcCtD
Topiramate—Dermatitis—Captopril—systemic scleroderma	0.000285	0.000333	CcSEcCtD
Topiramate—Somnolence—Lisinopril—systemic scleroderma	0.000285	0.000333	CcSEcCtD
Topiramate—Headache—Captopril—systemic scleroderma	0.000283	0.000331	CcSEcCtD
Topiramate—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000283	0.000331	CcSEcCtD
Topiramate—Dyspepsia—Lisinopril—systemic scleroderma	0.000282	0.00033	CcSEcCtD
Topiramate—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000281	0.000329	CcSEcCtD
Topiramate—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000281	0.000329	CcSEcCtD
Topiramate—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000281	0.000328	CcSEcCtD
Topiramate—Asthma—Methotrexate—systemic scleroderma	0.00028	0.000327	CcSEcCtD
Topiramate—Infection—Mycophenolate mofetil—systemic scleroderma	0.000279	0.000326	CcSEcCtD
Topiramate—Decreased appetite—Lisinopril—systemic scleroderma	0.000278	0.000326	CcSEcCtD
Topiramate—Eosinophilia—Methotrexate—systemic scleroderma	0.000277	0.000324	CcSEcCtD
Topiramate—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000277	0.000323	CcSEcCtD
Topiramate—Fatigue—Lisinopril—systemic scleroderma	0.000276	0.000323	CcSEcCtD
Topiramate—Shock—Mycophenolate mofetil—systemic scleroderma	0.000276	0.000323	CcSEcCtD
Topiramate—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000275	0.000322	CcSEcCtD
Topiramate—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000275	0.000321	CcSEcCtD
Topiramate—Hypersensitivity—Leflunomide—systemic scleroderma	0.000275	0.000321	CcSEcCtD
Topiramate—Pancreatitis—Methotrexate—systemic scleroderma	0.000274	0.000321	CcSEcCtD
Topiramate—Pain—Lisinopril—systemic scleroderma	0.000274	0.00032	CcSEcCtD
Topiramate—Constipation—Lisinopril—systemic scleroderma	0.000274	0.00032	CcSEcCtD
Topiramate—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000274	0.00032	CcSEcCtD
Topiramate—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000273	0.000319	CcSEcCtD
Topiramate—Bradycardia—Prednisone—systemic scleroderma	0.000273	0.000319	CcSEcCtD
Topiramate—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000271	0.000317	CcSEcCtD
Topiramate—Diarrhoea—Azathioprine—systemic scleroderma	0.00027	0.000316	CcSEcCtD
Topiramate—Haemoglobin—Prednisone—systemic scleroderma	0.000269	0.000315	CcSEcCtD
Topiramate—Nausea—Captopril—systemic scleroderma	0.000269	0.000314	CcSEcCtD
Topiramate—Abdominal discomfort—Methotrexate—systemic scleroderma	0.000268	0.000313	CcSEcCtD
Topiramate—Haemorrhage—Prednisone—systemic scleroderma	0.000268	0.000313	CcSEcCtD
Topiramate—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000268	0.000313	CcSEcCtD
Topiramate—Asthenia—Leflunomide—systemic scleroderma	0.000267	0.000313	CcSEcCtD
Topiramate—Hallucination—Prednisone—systemic scleroderma	0.000266	0.000312	CcSEcCtD
Topiramate—Pancytopenia—Methotrexate—systemic scleroderma	0.000266	0.00031	CcSEcCtD
Topiramate—Feeling abnormal—Lisinopril—systemic scleroderma	0.000264	0.000309	CcSEcCtD
Topiramate—Pruritus—Leflunomide—systemic scleroderma	0.000264	0.000308	CcSEcCtD
Topiramate—Connective tissue disorder—Prednisone—systemic scleroderma	0.000263	0.000308	CcSEcCtD
Topiramate—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000262	0.000307	CcSEcCtD
Topiramate—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000262	0.000306	CcSEcCtD
Topiramate—Neutropenia—Methotrexate—systemic scleroderma	0.000261	0.000306	CcSEcCtD
Topiramate—Dysuria—Methotrexate—systemic scleroderma	0.000261	0.000306	CcSEcCtD
Topiramate—Dizziness—Azathioprine—systemic scleroderma	0.000261	0.000305	CcSEcCtD
Topiramate—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.00026	0.000304	CcSEcCtD
Topiramate—Erectile dysfunction—Methotrexate—systemic scleroderma	0.000257	0.000301	CcSEcCtD
Topiramate—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000256	0.000299	CcSEcCtD
Topiramate—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.000255	0.000298	CcSEcCtD
Topiramate—Asthenia—Mycophenolic acid—systemic scleroderma	0.000255	0.000298	CcSEcCtD
Topiramate—Diarrhoea—Leflunomide—systemic scleroderma	0.000255	0.000298	CcSEcCtD
Topiramate—Urticaria—Lisinopril—systemic scleroderma	0.000254	0.000298	CcSEcCtD
Topiramate—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000254	0.000297	CcSEcCtD
Topiramate—Body temperature increased—Lisinopril—systemic scleroderma	0.000253	0.000296	CcSEcCtD
Topiramate—Abdominal pain—Lisinopril—systemic scleroderma	0.000253	0.000296	CcSEcCtD
Topiramate—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000252	0.000295	CcSEcCtD
Topiramate—Pruritus—Mycophenolic acid—systemic scleroderma	0.000252	0.000294	CcSEcCtD
Topiramate—Vomiting—Azathioprine—systemic scleroderma	0.000251	0.000293	CcSEcCtD
Topiramate—Pneumonia—Methotrexate—systemic scleroderma	0.000251	0.000293	CcSEcCtD
Topiramate—Eye disorder—Prednisone—systemic scleroderma	0.00025	0.000293	CcSEcCtD
Topiramate—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.00025	0.000293	CcSEcCtD
Topiramate—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000249	0.000292	CcSEcCtD
Topiramate—Infestation NOS—Methotrexate—systemic scleroderma	0.000249	0.000291	CcSEcCtD
Topiramate—Infestation—Methotrexate—systemic scleroderma	0.000249	0.000291	CcSEcCtD
Topiramate—Rash—Azathioprine—systemic scleroderma	0.000249	0.000291	CcSEcCtD
Topiramate—Dermatitis—Azathioprine—systemic scleroderma	0.000249	0.000291	CcSEcCtD
Topiramate—Depression—Methotrexate—systemic scleroderma	0.000249	0.000291	CcSEcCtD
Topiramate—Flushing—Prednisone—systemic scleroderma	0.000249	0.000291	CcSEcCtD
Topiramate—Headache—Azathioprine—systemic scleroderma	0.000247	0.000289	CcSEcCtD
Topiramate—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.000247	0.000289	CcSEcCtD
Topiramate—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000247	0.000289	CcSEcCtD
Topiramate—Dizziness—Leflunomide—systemic scleroderma	0.000247	0.000288	CcSEcCtD
Topiramate—Renal failure—Methotrexate—systemic scleroderma	0.000245	0.000287	CcSEcCtD
Topiramate—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000244	0.000285	CcSEcCtD
Topiramate—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000243	0.000285	CcSEcCtD
Topiramate—Stomatitis—Methotrexate—systemic scleroderma	0.000243	0.000284	CcSEcCtD
Topiramate—Angiopathy—Prednisone—systemic scleroderma	0.000243	0.000284	CcSEcCtD
Topiramate—Conjunctivitis—Methotrexate—systemic scleroderma	0.000242	0.000283	CcSEcCtD
Topiramate—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000242	0.000283	CcSEcCtD
Topiramate—Immune system disorder—Prednisone—systemic scleroderma	0.000242	0.000283	CcSEcCtD
Topiramate—Pain—Mycophenolate mofetil—systemic scleroderma	0.00024	0.000281	CcSEcCtD
Topiramate—Constipation—Mycophenolate mofetil—systemic scleroderma	0.00024	0.000281	CcSEcCtD
Topiramate—Haematuria—Methotrexate—systemic scleroderma	0.000238	0.000278	CcSEcCtD
Topiramate—Vomiting—Leflunomide—systemic scleroderma	0.000237	0.000277	CcSEcCtD
Topiramate—Alopecia—Prednisone—systemic scleroderma	0.000237	0.000277	CcSEcCtD
Topiramate—Hypersensitivity—Lisinopril—systemic scleroderma	0.000236	0.000276	CcSEcCtD
Topiramate—Dizziness—Mycophenolic acid—systemic scleroderma	0.000235	0.000275	CcSEcCtD
Topiramate—Epistaxis—Methotrexate—systemic scleroderma	0.000235	0.000275	CcSEcCtD
Topiramate—Rash—Leflunomide—systemic scleroderma	0.000235	0.000275	CcSEcCtD
Topiramate—Dermatitis—Leflunomide—systemic scleroderma	0.000235	0.000275	CcSEcCtD
Topiramate—Mental disorder—Prednisone—systemic scleroderma	0.000235	0.000274	CcSEcCtD
Topiramate—Nausea—Azathioprine—systemic scleroderma	0.000234	0.000274	CcSEcCtD
Topiramate—Headache—Leflunomide—systemic scleroderma	0.000234	0.000273	CcSEcCtD
Topiramate—Erythema—Prednisone—systemic scleroderma	0.000233	0.000273	CcSEcCtD
Topiramate—Malnutrition—Prednisone—systemic scleroderma	0.000233	0.000273	CcSEcCtD
Topiramate—Agranulocytosis—Methotrexate—systemic scleroderma	0.000233	0.000272	CcSEcCtD
Topiramate—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000231	0.00027	CcSEcCtD
Topiramate—Asthenia—Lisinopril—systemic scleroderma	0.00023	0.000269	CcSEcCtD
Topiramate—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000229	0.000268	CcSEcCtD
Topiramate—Pruritus—Lisinopril—systemic scleroderma	0.000227	0.000265	CcSEcCtD
Topiramate—Vomiting—Mycophenolic acid—systemic scleroderma	0.000226	0.000264	CcSEcCtD
Topiramate—Haemoglobin—Methotrexate—systemic scleroderma	0.000225	0.000263	CcSEcCtD
Topiramate—Rash—Mycophenolic acid—systemic scleroderma	0.000224	0.000262	CcSEcCtD
Topiramate—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000224	0.000262	CcSEcCtD
Topiramate—Haemorrhage—Methotrexate—systemic scleroderma	0.000224	0.000262	CcSEcCtD
Topiramate—Hepatitis—Methotrexate—systemic scleroderma	0.000224	0.000262	CcSEcCtD
Topiramate—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000223	0.000261	CcSEcCtD
Topiramate—Headache—Mycophenolic acid—systemic scleroderma	0.000223	0.000261	CcSEcCtD
Topiramate—Pharyngitis—Methotrexate—systemic scleroderma	0.000222	0.00026	CcSEcCtD
Topiramate—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000222	0.000259	CcSEcCtD
Topiramate—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000222	0.000259	CcSEcCtD
Topiramate—Nausea—Leflunomide—systemic scleroderma	0.000221	0.000259	CcSEcCtD
Topiramate—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000221	0.000258	CcSEcCtD
Topiramate—Vision blurred—Prednisone—systemic scleroderma	0.00022	0.000257	CcSEcCtD
Topiramate—Urethral disorder—Methotrexate—systemic scleroderma	0.000219	0.000257	CcSEcCtD
Topiramate—Diarrhoea—Lisinopril—systemic scleroderma	0.000219	0.000256	CcSEcCtD
Topiramate—Ill-defined disorder—Prednisone—systemic scleroderma	0.000216	0.000253	CcSEcCtD
Topiramate—Visual impairment—Methotrexate—systemic scleroderma	0.000216	0.000252	CcSEcCtD
Topiramate—Anaemia—Prednisone—systemic scleroderma	0.000215	0.000252	CcSEcCtD
Topiramate—Agitation—Prednisone—systemic scleroderma	0.000214	0.00025	CcSEcCtD
Topiramate—Dizziness—Lisinopril—systemic scleroderma	0.000212	0.000248	CcSEcCtD
Topiramate—Erythema multiforme—Methotrexate—systemic scleroderma	0.000212	0.000247	CcSEcCtD
Topiramate—Nausea—Mycophenolic acid—systemic scleroderma	0.000211	0.000247	CcSEcCtD
Topiramate—Malaise—Prednisone—systemic scleroderma	0.00021	0.000246	CcSEcCtD
Topiramate—Vertigo—Prednisone—systemic scleroderma	0.000209	0.000245	CcSEcCtD
Topiramate—Eye disorder—Methotrexate—systemic scleroderma	0.000209	0.000245	CcSEcCtD
Topiramate—Syncope—Prednisone—systemic scleroderma	0.000209	0.000244	CcSEcCtD
Topiramate—Tinnitus—Methotrexate—systemic scleroderma	0.000209	0.000244	CcSEcCtD
Topiramate—Cardiac disorder—Methotrexate—systemic scleroderma	0.000208	0.000243	CcSEcCtD
Topiramate—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000207	0.000242	CcSEcCtD
Topiramate—Loss of consciousness—Prednisone—systemic scleroderma	0.000205	0.00024	CcSEcCtD
Topiramate—Vomiting—Lisinopril—systemic scleroderma	0.000204	0.000238	CcSEcCtD
Topiramate—Angiopathy—Methotrexate—systemic scleroderma	0.000203	0.000237	CcSEcCtD
Topiramate—Immune system disorder—Methotrexate—systemic scleroderma	0.000202	0.000236	CcSEcCtD
Topiramate—Rash—Lisinopril—systemic scleroderma	0.000202	0.000236	CcSEcCtD
Topiramate—Convulsion—Prednisone—systemic scleroderma	0.000202	0.000236	CcSEcCtD
Topiramate—Dermatitis—Lisinopril—systemic scleroderma	0.000202	0.000236	CcSEcCtD
Topiramate—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000202	0.000236	CcSEcCtD
Topiramate—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000201	0.000235	CcSEcCtD
Topiramate—Hypertension—Prednisone—systemic scleroderma	0.000201	0.000235	CcSEcCtD
Topiramate—Chills—Methotrexate—systemic scleroderma	0.000201	0.000235	CcSEcCtD
Topiramate—Headache—Lisinopril—systemic scleroderma	0.000201	0.000235	CcSEcCtD
Topiramate—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000199	0.000232	CcSEcCtD
Topiramate—Myalgia—Prednisone—systemic scleroderma	0.000198	0.000232	CcSEcCtD
Topiramate—Arthralgia—Prednisone—systemic scleroderma	0.000198	0.000232	CcSEcCtD
Topiramate—Anxiety—Prednisone—systemic scleroderma	0.000198	0.000231	CcSEcCtD
Topiramate—Alopecia—Methotrexate—systemic scleroderma	0.000198	0.000231	CcSEcCtD
Topiramate—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000197	0.00023	CcSEcCtD
Topiramate—Discomfort—Prednisone—systemic scleroderma	0.000196	0.000229	CcSEcCtD
Topiramate—Mental disorder—Methotrexate—systemic scleroderma	0.000196	0.000229	CcSEcCtD
Topiramate—Malnutrition—Methotrexate—systemic scleroderma	0.000195	0.000228	CcSEcCtD
Topiramate—Erythema—Methotrexate—systemic scleroderma	0.000195	0.000228	CcSEcCtD
Topiramate—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000192	0.000225	CcSEcCtD
Topiramate—Dysgeusia—Methotrexate—systemic scleroderma	0.000191	0.000223	CcSEcCtD
Topiramate—Nausea—Lisinopril—systemic scleroderma	0.00019	0.000222	CcSEcCtD
Topiramate—Oedema—Prednisone—systemic scleroderma	0.00019	0.000222	CcSEcCtD
Topiramate—Infection—Prednisone—systemic scleroderma	0.000189	0.000221	CcSEcCtD
Topiramate—Back pain—Methotrexate—systemic scleroderma	0.000188	0.00022	CcSEcCtD
Topiramate—Shock—Prednisone—systemic scleroderma	0.000187	0.000219	CcSEcCtD
Topiramate—Nervous system disorder—Prednisone—systemic scleroderma	0.000187	0.000218	CcSEcCtD
Topiramate—Tachycardia—Prednisone—systemic scleroderma	0.000186	0.000217	CcSEcCtD
Topiramate—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000186	0.000217	CcSEcCtD
Topiramate—Skin disorder—Prednisone—systemic scleroderma	0.000185	0.000216	CcSEcCtD
Topiramate—Hyperhidrosis—Prednisone—systemic scleroderma	0.000184	0.000215	CcSEcCtD
Topiramate—Vision blurred—Methotrexate—systemic scleroderma	0.000184	0.000215	CcSEcCtD
Topiramate—Anorexia—Prednisone—systemic scleroderma	0.000181	0.000212	CcSEcCtD
Topiramate—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000181	0.000211	CcSEcCtD
Topiramate—Anaemia—Methotrexate—systemic scleroderma	0.00018	0.000211	CcSEcCtD
Topiramate—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000178	0.000209	CcSEcCtD
Topiramate—Rash—Mycophenolate mofetil—systemic scleroderma	0.000177	0.000207	CcSEcCtD
Topiramate—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000177	0.000207	CcSEcCtD
Topiramate—Headache—Mycophenolate mofetil—systemic scleroderma	0.000176	0.000206	CcSEcCtD
Topiramate—Malaise—Methotrexate—systemic scleroderma	0.000176	0.000205	CcSEcCtD
Topiramate—Vertigo—Methotrexate—systemic scleroderma	0.000175	0.000205	CcSEcCtD
Topiramate—Leukopenia—Methotrexate—systemic scleroderma	0.000174	0.000204	CcSEcCtD
Topiramate—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000173	0.000203	CcSEcCtD
Topiramate—Insomnia—Prednisone—systemic scleroderma	0.000172	0.000201	CcSEcCtD
Topiramate—Paraesthesia—Prednisone—systemic scleroderma	0.000171	0.0002	CcSEcCtD
Topiramate—Cough—Methotrexate—systemic scleroderma	0.00017	0.000199	CcSEcCtD
Topiramate—Convulsion—Methotrexate—systemic scleroderma	0.000169	0.000197	CcSEcCtD
Topiramate—Dyspepsia—Prednisone—systemic scleroderma	0.000167	0.000196	CcSEcCtD
Topiramate—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000167	0.000195	CcSEcCtD
Topiramate—Myalgia—Methotrexate—systemic scleroderma	0.000166	0.000194	CcSEcCtD
Topiramate—Chest pain—Methotrexate—systemic scleroderma	0.000166	0.000194	CcSEcCtD
Topiramate—Arthralgia—Methotrexate—systemic scleroderma	0.000166	0.000194	CcSEcCtD
Topiramate—Decreased appetite—Prednisone—systemic scleroderma	0.000165	0.000193	CcSEcCtD
Topiramate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000165	0.000193	CcSEcCtD
Topiramate—Fatigue—Prednisone—systemic scleroderma	0.000164	0.000192	CcSEcCtD
Topiramate—Discomfort—Methotrexate—systemic scleroderma	0.000164	0.000192	CcSEcCtD
Topiramate—Constipation—Prednisone—systemic scleroderma	0.000163	0.00019	CcSEcCtD
Topiramate—Confusional state—Methotrexate—systemic scleroderma	0.00016	0.000187	CcSEcCtD
Topiramate—Infection—Methotrexate—systemic scleroderma	0.000158	0.000185	CcSEcCtD
Topiramate—Feeling abnormal—Prednisone—systemic scleroderma	0.000157	0.000183	CcSEcCtD
Topiramate—Nervous system disorder—Methotrexate—systemic scleroderma	0.000156	0.000182	CcSEcCtD
Topiramate—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000156	0.000182	CcSEcCtD
Topiramate—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000156	0.000182	CcSEcCtD
Topiramate—Skin disorder—Methotrexate—systemic scleroderma	0.000154	0.000181	CcSEcCtD
Topiramate—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000154	0.00018	CcSEcCtD
Topiramate—Anorexia—Methotrexate—systemic scleroderma	0.000152	0.000177	CcSEcCtD
Topiramate—Urticaria—Prednisone—systemic scleroderma	0.000151	0.000177	CcSEcCtD
Topiramate—Body temperature increased—Prednisone—systemic scleroderma	0.00015	0.000176	CcSEcCtD
Topiramate—Abdominal pain—Prednisone—systemic scleroderma	0.00015	0.000176	CcSEcCtD
Topiramate—Hypotension—Methotrexate—systemic scleroderma	0.000149	0.000174	CcSEcCtD
Topiramate—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000145	0.000169	CcSEcCtD
Topiramate—Insomnia—Methotrexate—systemic scleroderma	0.000144	0.000168	CcSEcCtD
Topiramate—Paraesthesia—Methotrexate—systemic scleroderma	0.000143	0.000167	CcSEcCtD
Topiramate—Dyspnoea—Methotrexate—systemic scleroderma	0.000142	0.000166	CcSEcCtD
Topiramate—Somnolence—Methotrexate—systemic scleroderma	0.000141	0.000165	CcSEcCtD
Topiramate—Hypersensitivity—Prednisone—systemic scleroderma	0.00014	0.000164	CcSEcCtD
Topiramate—Dyspepsia—Methotrexate—systemic scleroderma	0.00014	0.000164	CcSEcCtD
Topiramate—Decreased appetite—Methotrexate—systemic scleroderma	0.000138	0.000162	CcSEcCtD
Topiramate—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000137	0.000161	CcSEcCtD
Topiramate—Fatigue—Methotrexate—systemic scleroderma	0.000137	0.00016	CcSEcCtD
Topiramate—Asthenia—Prednisone—systemic scleroderma	0.000136	0.00016	CcSEcCtD
Topiramate—Pain—Methotrexate—systemic scleroderma	0.000136	0.000159	CcSEcCtD
Topiramate—Pruritus—Prednisone—systemic scleroderma	0.000135	0.000157	CcSEcCtD
Topiramate—Feeling abnormal—Methotrexate—systemic scleroderma	0.000131	0.000153	CcSEcCtD
Topiramate—Diarrhoea—Prednisone—systemic scleroderma	0.00013	0.000152	CcSEcCtD
Topiramate—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.00013	0.000152	CcSEcCtD
Topiramate—Urticaria—Methotrexate—systemic scleroderma	0.000126	0.000148	CcSEcCtD
Topiramate—Dizziness—Prednisone—systemic scleroderma	0.000126	0.000147	CcSEcCtD
Topiramate—Abdominal pain—Methotrexate—systemic scleroderma	0.000126	0.000147	CcSEcCtD
Topiramate—Body temperature increased—Methotrexate—systemic scleroderma	0.000126	0.000147	CcSEcCtD
Topiramate—Vomiting—Prednisone—systemic scleroderma	0.000121	0.000141	CcSEcCtD
Topiramate—Rash—Prednisone—systemic scleroderma	0.00012	0.00014	CcSEcCtD
Topiramate—Dermatitis—Prednisone—systemic scleroderma	0.00012	0.00014	CcSEcCtD
Topiramate—Headache—Prednisone—systemic scleroderma	0.000119	0.000139	CcSEcCtD
Topiramate—Hypersensitivity—Methotrexate—systemic scleroderma	0.000117	0.000137	CcSEcCtD
Topiramate—Asthenia—Methotrexate—systemic scleroderma	0.000114	0.000133	CcSEcCtD
Topiramate—Nausea—Prednisone—systemic scleroderma	0.000113	0.000132	CcSEcCtD
Topiramate—Pruritus—Methotrexate—systemic scleroderma	0.000112	0.000132	CcSEcCtD
Topiramate—Diarrhoea—Methotrexate—systemic scleroderma	0.000109	0.000127	CcSEcCtD
Topiramate—Dizziness—Methotrexate—systemic scleroderma	0.000105	0.000123	CcSEcCtD
Topiramate—Vomiting—Methotrexate—systemic scleroderma	0.000101	0.000118	CcSEcCtD
Topiramate—Rash—Methotrexate—systemic scleroderma	0.0001	0.000117	CcSEcCtD
Topiramate—Dermatitis—Methotrexate—systemic scleroderma	0.0001	0.000117	CcSEcCtD
Topiramate—Headache—Methotrexate—systemic scleroderma	9.96e-05	0.000116	CcSEcCtD
Topiramate—Nausea—Methotrexate—systemic scleroderma	9.44e-05	0.00011	CcSEcCtD
